Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
apalutamide + androgen-deprivation therapy
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Apalutamide + androgen-deprivation therapy** is a combination regimen used primarily for the treatment of **metastatic hormone-sensitive prostate cancer** (mHSPC) and **non-metastatic castration-resistant prostate cancer** (nmCRPC)[3][5]. Apalutamide is a second-generation androgen receptor inhibitor that blocks androgen receptor signaling by binding directly to the receptor and inhibiting transcription of androgen-responsive genes[4]. Androgen-deprivation therapy (ADT) typically involves medical or surgical castration to reduce circulating testosterone, which is required for prostate cancer cell growth. Clinical trials (TITAN and SPARTAN) have shown that adding apalutamide to ADT improves overall survival, progression-free survival, and reduces the risk of metastasis or death in these patient populations compared to ADT alone[3][5][1].
- Brand names
- Erleada + ADT
- Other names
- apalutamide + ADTapalutamide + androgen deprivation therapy
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on apalutamide + androgen-deprivation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on apalutamide + androgen-deprivation therapy.